• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

    1/24/24 2:27:16 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    SC 13G/A 1 ie00bgh1m568_012424.txt ie00bgh1m568_012424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) Perrigo Company plc -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BGH1M56 -------------------------------------------------------- (SEDOL Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SEDOL No. BGH1M56 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 12525460 (6) Shared voting power 0 (7) Sole dispositive power 13342622 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 13342622 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 9.8% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- Perrigo Company plc Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- The Sharp Building, Hogan Place Dublin 2 Ireland D02 TY74 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) SEDOL No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 13342622 Percent of class 9.8% Number of shares as to which such person has: Sole power to vote or to direct the vote 12525460 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 13342622 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Perrigo Company plc. No one person's interest in the common stock of Perrigo Company plc is more than five percent of the total outstanding common shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 24, 2024 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary BlackRock Life Limited BlackRock International Limited BlackRock Advisors, LLC Aperio Group, LLC BlackRock (Netherlands) B.V. BlackRock Fund Advisors* BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. BlackRock Japan Co., Ltd. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC BlackRock Investment Management (UK) Limited BlackRock Asset Management Canada Limited BlackRock Investment Management (Australia) Limited BlackRock Advisors (UK) Limited BlackRock (Singapore) Limited BlackRock Fund Managers Ltd *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary
    Get the next $PRGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    11/11/2021$59.00 → $55.00Outperform
    Raymond James
    More analyst ratings

    $PRGO
    SEC Filings

    See more
    • SEC Form S-8 filed by Perrigo Company plc

      S-8 - PERRIGO Co plc (0001585364) (Filer)

      5/7/25 5:23:16 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Perrigo Company plc

      10-Q - PERRIGO Co plc (0001585364) (Filer)

      5/7/25 2:46:04 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Company plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PERRIGO Co plc (0001585364) (Filer)

      5/7/25 6:41:21 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andersen Svend bought $27,900 worth of Ordinary Shares (1,000 units at $27.90), increasing direct ownership by 0.99% to 101,853 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      5/31/24 5:04:45 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ives Alison exercised 1,698 units of Ordinary Shares at a strike of $27.26, covered exercise/tax liability with 1,262 units of Ordinary Shares and bought $67,877 worth of Ordinary Shares (2,490 units at $27.26), increasing direct ownership by 24% to 15,372 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      3/7/24 9:58:50 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ives Alison bought $40,850 worth of Ordinary Shares (1,545 units at $26.44), increasing direct ownership by 14% to 12,446 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      3/7/24 9:54:19 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

      For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

      7/13/23 8:32:15 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Perrigo downgraded by Argus

      Argus downgraded Perrigo from Buy to Hold

      1/14/25 8:38:48 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

      1/6/25 8:24:36 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Perrigo with a new price target

      Jefferies resumed coverage of Perrigo with a rating of Hold and set a new price target of $30.00 from $50.00 previously

      9/24/24 8:23:03 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    See more
    • Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

      Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

      1/6/25 8:00:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary

      Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General Counsel DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry. President and CEO Patrick Lockwood-Taylor commented, "I am very excited to welcome Charles to the Perrigo leadership team. His strat

      9/4/24 8:00:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer

      DUBLIN, Aug. 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer. In this newly created position, Dr. Ball will be responsible for an enterprise-wide marketing strategy that incorporates deep understanding of consumer needs and translates those into winning brand strategies, tactics, and actions. He will also evaluate untapped market opportunities and develop strategies to scale the Company's brand-building efforts.

      8/19/24 8:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Financials

    Live finance-specific insights

    See more

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

      Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested

      5/7/25 6:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Announces Quarterly Dividend

      DUBLIN, April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit

      4/30/25 10:23:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025

      DUBLIN, April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7th, 2025, and host a conference call beginning at 8:30 A.M. (EST).  The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay o

      4/23/25 4:47:00 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Perrigo Company plc

      SC 13G - PERRIGO Co plc (0001585364) (Subject)

      10/31/24 11:55:03 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Perrigo Company plc

      SC 13G - PERRIGO Co plc (0001585364) (Subject)

      2/13/24 1:05:29 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

      SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

      1/24/24 2:27:16 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

      Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested

      5/7/25 6:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Announces Quarterly Dividend

      DUBLIN, April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit

      4/30/25 10:23:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025

      DUBLIN, April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7th, 2025, and host a conference call beginning at 8:30 A.M. (EST).  The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay o

      4/23/25 4:47:00 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Samuelson Jonas

      4 - PERRIGO Co plc (0001585364) (Issuer)

      4/11/25 2:25:14 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Samuelson Jonas claimed no ownership of stock in the company (SEC Form 3)

      3 - PERRIGO Co plc (0001585364) (Issuer)

      4/11/25 10:58:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP and CSO Lennox Abigail

      4 - PERRIGO Co plc (0001585364) (Issuer)

      4/8/25 11:23:10 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care